Side-by-side comparison of AI visibility scores, market position, and capabilities
Rare disease drug discovery using patient-derived organoids and robotics to screen therapeutics matching real genetic mutations; YC and NSF backed with Stanford-validated pediatric heart disease breakthrough.
Rosebud Biosciences is a San Carlos-based drug discovery company that accelerates therapeutic development for rare diseases by screening drug candidates against patient-derived organoids — miniature 3D organ models grown from patients' own cells with matching genetic mutations — using robotic automation and machine learning to identify compounds that correct disease phenotypes at a scale impossible with traditional cell line testing. Founded in 2020 and backed by Y Combinator, NSF, and other investors with $440,000 in revenue, Rosebud has achieved Stanford-validated research breakthroughs published in prestigious scientific journals, including discovering a novel drug target for pediatric heart disease.
Kindful, nonprofit donor management/CRM platform (acquired by Bloomerang 2020), 1,000+ nonprofit customers, cloud-based fundraising software, online donation forms, donor analytics, email marketing, integrated with QuickBooks/Mailchimp, now part of Bloomerang suite
Kindful is a donor management and fundraising platform designed for nonprofit organizations to manage relationships, track donations, and execute fundraising campaigns. The company serves small to mid-sized nonprofits who need affordable, user-friendly software to organize donor data, process contributions, and measure fundraising effectiveness. Kindful provides tools for online giving, email marketing, event management, donor segmentation, and reporting that help nonprofits build stronger relationships with supporters, streamline fundraising operations, and increase donations while reducing administrative burden.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.